Research Solutions (RSSS) 10-Q 15 May 17 2017 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Mar. 31, 2017	May 10, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Entity Registrant Name	Research Solutions, Inc.
Entity Central Index Key	1,386,301
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Trading Symbol	RSSS
Entity Common Stock, Shares Outstanding		23,925,910

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2017	Jun. 30, 2016
Current assets:
Cash and cash equivalents	$ 5,242,978	$ 6,076,875
Accounts receivable, net of allowance of $47,510 and $52,084, respectively	5,186,517	5,761,860
Prepaid expenses and other current assets	196,553	164,610
Prepaid royalties	1,276,576	173,665
Total current assets	11,902,624	12,177,010
Other assets:
Property and equipment, net of accumulated depreciation of $682,849 and $642,051, respectively	83,662	82,207
Intangible assets, net of accumulated amortization of $602,779 and $546,679, respectively	58,499	104,848
Deposits and other assets	19,061	7,594
Right of use asset, net of accumulated amortization of $18,018	445,004	0
Total assets	12,508,850	12,371,659
Current liabilities:
Accounts payable and accrued expenses	6,338,404	5,690,768
Deferred revenue	1,163,813	639,834
Lease liability, current portion	88,124	0
Total current liabilities	7,590,341	6,330,602
Long-term liabilities:
Lease liability, long-term portion	357,063	0
Total liabilities	7,947,404	6,330,602
Commitments and contingencies
Stockholders’ equity:
Preferred stock; $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock; $0.001 par value; 100,000,000 shares authorized; 23,925,910 and 23,809,593 shares issued and outstanding, respectively	23,926	23,810
Additional paid-in capital	22,070,330	21,642,763
Accumulated deficit	(17,473,411)	(15,582,295)
Accumulated other comprehensive loss	(59,399)	(43,221)
Total stockholders’ equity	4,561,446	6,041,057
Total liabilities and stockholders’ equity	$ 12,508,850	$ 12,371,659

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets [Parenthetical] - USD ($)	Mar. 31, 2017	Jun. 30, 2016
Allowance for Doubtful Accounts Receivable, Current	$ 47,510	$ 52,084
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	682,849	642,051
Finite-Lived Intangible Assets, Accumulated Amortization	$ 602,779	$ 546,679
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	20,000,000	20,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	23,925,910	23,809,593
Common Stock, Shares, Outstanding	23,925,910	23,809,593
Use Rights [Member]
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$ 18,018	$ 18,018

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Revenue	$ 8,643,799	$ 8,724,217	$ 24,832,582	$ 26,066,544
Cost of revenue	6,914,793	6,959,203	19,976,167	21,150,881
Gross profit	1,729,006	1,765,014	4,856,415	4,915,663
Operating expenses:
Selling, general and administrative	2,334,189	1,665,090	6,633,521	5,244,267
Depreciation and amortization	33,906	30,310	96,801	61,144
Total operating expenses	2,368,095	1,695,400	6,730,322	5,305,411
Income (loss) from operations	(639,089)	69,614	(1,873,907)	(389,748)
Other income (expenses):
Interest expense	(3,000)	(6,389)	(9,000)	(14,382)
Other income (expense)	10,143	(25,639)	20,277	(18,229)
Total other income (expenses)	7,143	(32,028)	11,277	(32,611)
Income (loss) from operations before provision for income taxes	(631,946)	37,586	(1,862,630)	(422,359)
Provision for income taxes	(5,544)	(5,210)	(28,486)	(22,510)
Net income (loss)	(637,490)	32,376	(1,891,116)	(444,869)
Other comprehensive income (loss):
Foreign currency translation	(18,090)	(6,603)	(16,178)	(11,966)
Comprehensive income (loss)	$ (655,580)	$ 25,773	$ (1,907,294)	$ (456,835)
Basic income (loss) per common share:
Net income (loss) per share	$ (0.03)	$ 0	$ (0.08)	$ (0.03)
Basic weighted average common shares outstanding	23,265,939	17,707,900	23,199,010	17,642,449
Diluted income (loss) per common share:
Net income (loss) per share	$ (0.03)	$ 0	$ (0.08)	$ (0.03)
Diluted weighted average common shares outstanding	23,265,939	18,464,000	23,199,010	17,642,449

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Stockholders' Equity - 9 months ended Mar. 31, 2017 - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Other Comprehensive Loss [Member]
Balance at Jun. 30, 2016	$ 6,041,057	$ 23,810	$ 21,642,763	$ (15,582,295)	$ (43,221)
Balance (in shares) at Jun. 30, 2016		23,809,593
Fair value of vested stock options	247,224	$ 0	247,224	0	0
Fair value of vested restricted common stock	270,787	$ 202	270,585	0	0
Fair value of vested restricted common stock (in shares)		203,275
Repurchase of common stock	(90,328)	$ (86)	(90,242)	0	0
Repurchase of common stock (in shares)		(86,958)
Net loss for the period	(1,891,116)	$ 0	0	(1,891,116)	0
Foreign currency translation	(16,178)	0	0	0	(16,178)
Balance at Mar. 31, 2017	$ 4,561,446	$ 23,926	$ 22,070,330	$ (17,473,411)	$ (59,399)
Balance (in shares) at Mar. 31, 2017		23,925,910

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flow from operating activities:
Net loss	$ (1,891,116)	$ (444,869)
Adjustment to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	96,801	61,145
Amortization of lease right	18,018	0
Fair value of vested stock options	247,224	245,523
Fair value of vested restricted common stock	270,787	276,360
Modification cost of options issued to directors	0	29,815
Changes in operating assets and liabilities:
Accounts receivable	575,343	(614,001)
Prepaid expenses and other current assets	(31,943)	(63,367)
Prepaid royalties	(1,102,911)	184,680
Deposits and other assets	(11,467)	106
Accounts payable and accrued expenses	647,636	564,290
Deferred revenue	523,979	542,400
Lease liability	(17,835)	0
Net cash provided by (used in) operating activities	(675,484)	782,082
Cash flow from investing activities:
Purchase of property and equipment	(42,316)	(49,784)
Purchase of intangible assets	(9,751)	(130,800)
Net cash used in investing activities	(52,067)	(180,584)
Cash flow from financing activities:
Advance under line of credit	0	1,000,000
Payment under line of credit	0	(1,000,000)
Common stock repurchase and retirement	(90,328)	(20,147)
Net cash used in financing activities	(90,328)	(20,147)
Effect of exchange rate changes	(16,018)	(11,539)
Net increase (decrease) in cash and cash equivalents	(833,897)	569,812
Cash and cash equivalents, beginning of period	6,076,875	1,354,158
Cash and cash equivalents, end of period	5,242,978	1,923,970
Supplemental disclosures of cash flow information:
Cash paid for income taxes	28,486	22,510
Cash paid for interest	9,000	14,382
Supplemental noncash investing and financing activities:
Acquisition of leased asset and lease liability	$ 463,022	$ 0

Organization, Nature of Busines

Organization, Nature of Business and Basis of Presentation	9 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Nature of Business and Basis of Presentation	Note 1. Organization, Nature of Business and Basis of Presentation Organization Research Solutions, Inc. (the “Company,” “Research Solutions,” “we,” “us” or “our”) was incorporated in the State of Nevada on November 2, 2006. On March 4, 2013, we consummated a merger with DYSC Subsidiary Corporation, our wholly-owned subsidiary, pursuant to which we, in connection with such merger, amended our Articles of Incorporation to change our name to Research Solutions, Inc. (formerly Derycz Scientific, Inc.). Research Solutions, Inc. is a publicly traded holding company with two wholly owned subsidiaries: Reprints Desk, Inc., a Delaware corporation (“Reprints Desk”) and Reprints Desk Latin America S. de R.L. de C.V, an entity organized under the laws of Mexico (“Reprints Desk Latin America”). Nature of Business We provide a cloud based software-as-a-service (“SaaS”) research intelligence platform that allows on-demand access to scientific, technical, and medical (“STM”) information for life science companies, academic institutions, and other research-intensive organizations. We provide three service offerings to our customers: Article Galaxy SaaS Platforms (“Platform(s)”), Article Galaxy Transactions (“Transactions”), and Reprints and ePrints. Platforms Our cloud-based SaaS solution consists of proprietary software and Internet-based interfaces. Legacy functionality allows customers to initiate orders, manage transactions, obtain reporting, automate authentication, and connect seamlessly to corporate intranets. Customers can also enhance the information resources they already own or access via subscriptions or internal libraries, as well as organize workgroups to collaborate around scientific and technical information. New functionality has recently been added to our Platform in the form of interactive app-like gadgets. An alternative to manual data filtering and extraction, gadgets are designed to gather, augment, and extract data across a variety of formats, including bibliographic citations, tables of contents, RSS feeds, PDF files, XML feeds, and web content. We are rapidly developing new gadgets in order to build an ecosystem of gadgets. Together, these gadgets will provide researchers with an “all in one” toolkit, delivering efficiencies in core research workflows and knowledge creation processes. Our Platform is deployed as a single system across our entire customer base. Customers access the Platform securely through online web interfaces and via web service APIs, which enable customers to leverage features and functionality from within proprietary and other 3rd party software systems. The Platform can also be configured to satisfy a customer’s individual preferences in areas such as user experience, business processes, and spend management. The Platform benefits from efficiencies in scalability, stability and development costs, resulting in significant advantages versus multiple instance or installed desktop software alternatives. We leverage these technical efficiencies to fuel rapid innovation and competitive advantage. Transactions Our Platform provides our customers with a single source to the universe of published STM content that includes over seventy million existing STM articles and over one million newly published STM articles each year. Our Platform allows customers to find and download in digital format STM articles that are critical to their research. In addition, it facilitates customers’ compliance with applicable copyright laws. Researchers and knowledge workers in life science and other research-intensive organizations generally require single copies of published STM journal articles for use in their research activities. They place orders with us for the articles they need and we source and electronically deliver the requested content to them generally in under an hour. This service is known in the industry as single article delivery or document delivery. We also obtain the necessary permissions from the content publisher so that our customer’s use complies with applicable copyright laws. We have arrangements with numerous content publishers that allow us to distribute their content. The majority of these publishers provide us with electronic access to their content, which allows us to electronically deliver single articles to our customers often in a matter of minutes. Reprints and ePrints Marketing departments in life science and other research-intensive organizations generally require large quantities of printed copies of published STM journal articles called “Reprints” that are distributed to physicians and at conferences. We obtain the necessary permissions from the content publisher so that our customer’s use complies with applicable copyright laws. The majority of content publishers print their content in-house and prohibit others from printing their content; however, when not prohibited by the content publisher, we use third parties to print Reprint orders. Electronic copies, called “ePrints”, are also used for distribution through the Internet and other electronic mechanisms. We have developed proprietary ePrint software that increases the efficiency of our customers’ content purchases by transitioning from paper Reprints to electronic ePrints, and by improving compliance with applicable copyright laws and promotional regulations within the life science industry. Reprints and ePrints are charged on a transactional basis and order volume typically fluctuates from month to month based on customer marketing budgets and the existence of STM journal articles that fit customer requirements. Principles of Consolidation The accompanying financial statements are consolidated and include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation. Basis of Presentation The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2016 filed with the SEC. The condensed consolidated balance sheet as of June 30, 2016 included herein was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company's financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates. These estimates and assumptions include estimates for reserves of uncollectible accounts, analysis of impairments of recorded intangibles, accruals for potential liabilities and assumptions made in valuing equity instruments issued for services or acquisitions. Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents and accounts receivable. The Company places its cash with high quality financial institutions and at times may exceed the FDIC $ 250,000 Cash denominated in Euros with a US Dollar equivalent of $ 181,634 76,793 The Company has no customers that represent 10 The Company has no customers that accounted for greater than 10 The following table summarizes vendor concentrations: Three Months Ended Nine Months Ended March 31, March 31, 2017 2016 2017 2016 Vendor A 16 % 18 % 18 % 16 % Vendor B * * * 13 % * Less than 10% The Company’s policy is to recognize revenue when services have been performed, risk of loss and title to the product transfers to the customer, the selling price is fixed or determinable, and collectability is reasonably assured. We generate revenue by providing three service offerings to our customers: Platforms, Transactions, and Reprints and ePrints. Platforms We charge a subscription fee that allows customers to access and utilize our SaaS platform. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue. Transactions We charge a transactional service fee for the electronic delivery of single articles, and a corresponding copyright fee for the permitted use of the content. This service is known in the industry as single article delivery or document delivery. We recognize revenue from single article delivery services upon delivery to the customer only when the selling price is fixed or determinable, and collectability is reasonably assured. Reprints and ePrints We charge a transactional fee for each Reprint or ePrint order and are responsible for printing and delivery of Reprint orders, and the electronic delivery and, in some cases, the electronic delivery mechanism of ePrint orders. The majority of content publishers print their content in-house and prohibit others from printing their content; however, when not prohibited by the content publisher, we use third parties to print Reprint orders. We recognize revenue from Reprints and ePrints services upon shipment or electronic delivery to the customer only when the selling price is fixed or determinable, and collectability is reasonably assured. Customer deposits and billings or payments received in advance of revenue recognition are recorded as deferred revenue. Platforms Cost of Platform revenue consists primarily of personnel costs of our operations team, and to a lesser extent managed hosting providers and other third-party service and data providers. Transactions Cost of Transaction revenue consists primarily of the respective copyright fee for the permitted use of the content, less a discount in most cases, and to a much lesser extent, personnel costs of our operations team and third-party service providers. Reprints and ePrints Cost of Reprints and ePrints revenue consists primarily of the respective copyright fee for the permitted use of the content, and to a much lesser extent, personnel costs of our operations team, shipping, and printing. The Company periodically issues stock options, warrants and restricted stock to employees and non-employees for services, in capital raising transactions, and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic 718 of the Financial Accounting Standards Board (FASB) Accounting Standards Codification, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of stock option and warrant awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company's Statements of Operations. The Company estimates the fair value of restricted stock awards to employees and directors using the market price of the Company’s common stock on the date of grant, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company's Statements of Operations. The Company accounts for share-based payments to non-employees in accordance with Topic 505 of the FASB Accounting Standards Codification, whereby the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates. The accompanying consolidated financial statements are presented in United States dollars, the functional currency of the Company. Capital accounts of foreign subsidiaries are translated into US Dollars from foreign currency at their historical exchange rates when the capital transactions occurred. Assets and liabilities are translated at the exchange rate as of the balance sheet date. Income and expenditures are translated at the average exchange rate of the period. Although the majority of our revenue and costs are in US dollars, the costs of Reprints Desk Latin America are in Mexican Pesos. As a result, currency exchange fluctuations may impact our revenue and the costs of our operations. We currently do not engage in any currency hedging activities. Gains and losses from foreign currency transactions, which result from a change in exchange rates between the functional currency and the currency in which a foreign currency transaction is denominated, are included in selling, general and administrative expenses and amounted to a loss of $ 6,272 27,227 4,293 The following table summarizes the exchange rates used: Nine Months Ended Year Ended March 31, June 30, 2017 2016 2016 2015 Period end Euro : US Dollar exchange rate 1.08 1.14 1.11 1.11 Average period Euro : US Dollar exchange rate 1.09 1.10 1.11 1.20 Period end Mexican Peso : US Dollar exchange rate 0.05 0.06 0.05 0.06 Average period Mexican Peso : US Dollar exchange rate 0.05 0.06 0.06 0.07 Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, excluding shares of unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted earnings per share is computed by dividing the net income applicable to common stock holders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted. Potential common shares are excluded from the computation when their effect is antidilutive. At March 31, 2017 potentially dilutive securities include options to acquire 3,125,951 1,985,000 2,551,028 205,000 Basic and diluted net loss per common share is the same for the three and nine months ended March 31, 2017 and the nine months ended March 31, 2016, because all stock options, warrants, and unvested restricted common stock are anti-dilutive. For the three months ended March 31, 2016, the calculation of diluted earnings per share includes unvested restricted common stock, stock options, and warrants, calculated under the treasury stock method. In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers In February 2016, the FASB issued ASU No. 2016-02, Leases. ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company adopted ASU No. 2016-02 for a new lease entered into during the period. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

Line of Credit

Line of Credit	9 Months Ended
	Mar. 31, 2017
Line of Credit Facility [Abstract]
Line of Credit	Note 3. Line of Credit The Company entered into a Loan and Security Agreement with Silicon Valley Bank (“SVB”) on July 23, 2010, which, as amended, provides for a revolving line of credit for the lesser of $ 4,000,000 80 October 31, 2017 Financial covenants include maintaining a ratio of quick assets to current liabilities of at least 0.8 to 1.0, and maintaining tangible net worth of $600,000, plus 50% of net income for the fiscal quarter ended from and after December 31, 2015, plus 50% of the dollar value of equity issuances after October 1, 2015 and the principal amount of subordinated debt. 2.25 800,000 5.75 There were no outstanding borrowings under the line as of March 31, 2017 and June 30, 2016, respectively. As of March 31, 2017 and June 30, 2016, approximately $ 2,945,000 3,390,000

Obligations Leases

Obligations Leases	9 Months Ended
	Mar. 31, 2017
Leases [Abstract]
Obligations Leases	Note 4. Obligations Leases During the period ended March 31, 2017, the Company entered into a 48 month non-cancellable lease for its office facilities that will require monthly payments ranging from $10,350 to $11,475 through January 2021. In accounting for the lease, the Company adopted ASU 2016-02, Leases which requires a lessee to record a right-of-use asset and a corresponding lease liability at the inception of the lease initially measured at the present value of the lease payments. The Company classified the lease as an operating lease and determined that the fair value of the lease liability at the inception of the lease was $463,000 using a discount rate of 3.75%. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Mar. 31, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Note 5. Stockholders’ Equity Stock Options In December 2007, we established the 2007 Equity Compensation Plan (the “Plan”). The Plan was approved by our board of directors and stockholders. The purpose of the Plan is to grant stock and options to our employees, directors and key consultants to purchase our common stock. On November 10, 2016, the maximum number of shares of common stock that may be issued pursuant to awards granted under the Plan (including issuance of restricted common stock) increased from 5,000,000 7,000,000 2,231,753 The majority of awards issued under the Plan vest immediately or over three years, with a one year cliff vesting period, and have a term of ten years. Stock-based compensation cost is measured at the grant date, based on the fair value of the awards that are ultimately expected to vest, and recognized on a straight-line basis over the requisite service period, which is generally the vesting period. All Options Vested Options Unvested Options Weighted Weighted Weighted Average Average Average Exercise Exercise Exercise Shares Price Shares Price Shares Price Outstanding at June 30, 2016 2,717,193 1.16 2,517,333 1.17 199,860 1.06 Granted 408,758 1.05 325,000 1.05 83,758 1.05 Options vesting - - 52,224 1.09 (52,224) 1.09 Exercised - - - - - - Forfeited/Cancelled - - - - - - Outstanding at March 31, 2017 3,125,951 $ 1.15 2,894,557 $ 1.15 231,394 $ 1.05 The weighted average remaining contractual life of all options outstanding as of March 31, 2017 was 5.81 5.54 185,399 178,278 During the nine months ended March 31, 2017, the Company granted 408,758 248,549 77.8 81.4 1.27 2.06 5 6 247,224 113,069 Option Remaining Exercise Options Contractual Options Price Outstanding Life (in years) Exercisable $ 0.59 8,150 8.91 3,396 0.60 5,000 8.87 2,500 0.65 6,150 7.61 5,125 0.70 225,000 8.68 225,000 0.77 59,500 7.39 55,792 0.80 16,000 8.39 16,000 0.90 25,667 8.35 21,222 0.97 6,000 9.40 - 1.00 370,890 2.53 364,916 1.02 287,000 3.33 287,000 1.05 507,529 9.33 430,630 1.07 53,898 5.55 53,898 1.09 166,165 9.15 43,750 1.10 255,000 8.25 255,000 1.14 3,674 9.89 - 1.15 228,000 5.86 228,000 1.20 31,414 7.14 31,414 1.25 32,000 5.88 32,000 1.30 263,000 4.93 263,000 1.50 380,000 0.81 380,000 1.75 1,067 6.83 1,067 1.80 169,425 6.48 169,425 1.85 24,000 6.14 24,000 1.97 1,422 6.65 1,422 Total 3,125,951 2,894,557 Warrants Weighted Average Number of Exercise Warrants Price Outstanding, June 30, 2016 1,990,000 1.25 Granted - - Exercised - - Expired/Cancelled (5,000) 3.75 Outstanding, March 31, 2017 1,985,000 $ 1.25 Exercisable, June 30, 2016 1,990,000 $ 1.25 Exercisable, March 31, 2017 1,985,000 $ 1.25 There was no intrinsic value for all warrants outstanding as of March 31, 2017, based on the fair value of the Company’s common stock on March 31, 2017. Remaining Warrant Warrants Contractual Warrants Exercise Price Outstanding Life (in years) Exercisable $ 1.19 100,000 4.73 100,000 1.25 1,885,000 4.20 1,885,000 Total 1,985,000 1,985,000 Restricted Common Stock Prior to July 1, 2016, the Company issued 1,303,687 1,286,474 783,845 During the nine months ended March 31, 2017, the Company issued an additional 203,275 210,365 0.97 1.14 The total fair value of restricted common stock vested during the nine months ended March 31, 2017 was $ 270,788 442,567 Weighted Average Number of Grant Date Shares Fair Value Non-vested, June 30, 2016 706,642 0.82 Granted 203,275 1.03 Vested (359,703) 0.81 Forfeited - - Non-vested, March 31, 2017 550,213 $ 0.90 Common Stock Repurchase and Retirement During the nine months ended March 31, 2017, the Company repurchased 86,958 1.04 90,329

Summary of Significant Accoun12

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates. These estimates and assumptions include estimates for reserves of uncollectible accounts, analysis of impairments of recorded intangibles, accruals for potential liabilities and assumptions made in valuing equity instruments issued for services or acquisitions.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents and accounts receivable. The Company places its cash with high quality financial institutions and at times may exceed the FDIC $ 250,000 Cash denominated in Euros with a US Dollar equivalent of $ 181,634 76,793 The Company has no customers that represent 10 The Company has no customers that accounted for greater than 10 The following table summarizes vendor concentrations: Three Months Ended Nine Months Ended March 31, March 31, 2017 2016 2017 2016 Vendor A 16 % 18 % 18 % 16 % Vendor B * * * 13 % * Less than 10%
Revenue Recognition	Revenue Recognition The Company’s policy is to recognize revenue when services have been performed, risk of loss and title to the product transfers to the customer, the selling price is fixed or determinable, and collectability is reasonably assured. We generate revenue by providing three service offerings to our customers: Platforms, Transactions, and Reprints and ePrints. Platforms We charge a subscription fee that allows customers to access and utilize our SaaS platform. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue. Transactions We charge a transactional service fee for the electronic delivery of single articles, and a corresponding copyright fee for the permitted use of the content. This service is known in the industry as single article delivery or document delivery. We recognize revenue from single article delivery services upon delivery to the customer only when the selling price is fixed or determinable, and collectability is reasonably assured. Reprints and ePrints We charge a transactional fee for each Reprint or ePrint order and are responsible for printing and delivery of Reprint orders, and the electronic delivery and, in some cases, the electronic delivery mechanism of ePrint orders. The majority of content publishers print their content in-house and prohibit others from printing their content; however, when not prohibited by the content publisher, we use third parties to print Reprint orders. We recognize revenue from Reprints and ePrints services upon shipment or electronic delivery to the customer only when the selling price is fixed or determinable, and collectability is reasonably assured.
Deferred Revenue	Deferred Revenue Customer deposits and billings or payments received in advance of revenue recognition are recorded as deferred revenue.
Cost of Revenue	Cost of Revenue Platforms Cost of Platform revenue consists primarily of personnel costs of our operations team, and to a lesser extent managed hosting providers and other third-party service and data providers. Transactions Cost of Transaction revenue consists primarily of the respective copyright fee for the permitted use of the content, less a discount in most cases, and to a much lesser extent, personnel costs of our operations team and third-party service providers. Reprints and ePrints Cost of Reprints and ePrints revenue consists primarily of the respective copyright fee for the permitted use of the content, and to a much lesser extent, personnel costs of our operations team, shipping, and printing.
Stock-Based Compensation	Stock-Based Compensation The Company periodically issues stock options, warrants and restricted stock to employees and non-employees for services, in capital raising transactions, and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic 718 of the Financial Accounting Standards Board (FASB) Accounting Standards Codification, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of stock option and warrant awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company's Statements of Operations. The Company estimates the fair value of restricted stock awards to employees and directors using the market price of the Company’s common stock on the date of grant, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company's Statements of Operations. The Company accounts for share-based payments to non-employees in accordance with Topic 505 of the FASB Accounting Standards Codification, whereby the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.
Foreign Currency	Foreign Currency The accompanying consolidated financial statements are presented in United States dollars, the functional currency of the Company. Capital accounts of foreign subsidiaries are translated into US Dollars from foreign currency at their historical exchange rates when the capital transactions occurred. Assets and liabilities are translated at the exchange rate as of the balance sheet date. Income and expenditures are translated at the average exchange rate of the period. Although the majority of our revenue and costs are in US dollars, the costs of Reprints Desk Latin America are in Mexican Pesos. As a result, currency exchange fluctuations may impact our revenue and the costs of our operations. We currently do not engage in any currency hedging activities. Gains and losses from foreign currency transactions, which result from a change in exchange rates between the functional currency and the currency in which a foreign currency transaction is denominated, are included in selling, general and administrative expenses and amounted to a loss of $ 6,272 27,227 4,293 The following table summarizes the exchange rates used: Nine Months Ended Year Ended March 31, June 30, 2017 2016 2016 2015 Period end Euro : US Dollar exchange rate 1.08 1.14 1.11 1.11 Average period Euro : US Dollar exchange rate 1.09 1.10 1.11 1.20 Period end Mexican Peso : US Dollar exchange rate 0.05 0.06 0.05 0.06 Average period Mexican Peso : US Dollar exchange rate 0.05 0.06 0.06 0.07
Net Income (Loss) Per Share	Net Income (Loss) Per Share Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, excluding shares of unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted earnings per share is computed by dividing the net income applicable to common stock holders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted. Potential common shares are excluded from the computation when their effect is antidilutive. At March 31, 2017 potentially dilutive securities include options to acquire 3,125,951 1,985,000 2,551,028 205,000 Basic and diluted net loss per common share is the same for the three and nine months ended March 31, 2017 and the nine months ended March 31, 2016, because all stock options, warrants, and unvested restricted common stock are anti-dilutive. For the three months ended March 31, 2016, the calculation of diluted earnings per share includes unvested restricted common stock, stock options, and warrants, calculated under the treasury stock method.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers In February 2016, the FASB issued ASU No. 2016-02, Leases. ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company adopted ASU No. 2016-02 for a new lease entered into during the period. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

Summary of Significant Accoun13

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Schedule of Concentration of Risk	The following table summarizes vendor concentrations: Three Months Ended Nine Months Ended March 31, March 31, 2017 2016 2017 2016 Vendor A 16 % 18 % 18 % 16 % Vendor B * * * 13 % * Less than 10%
Schedule Of Foreign Currency Exchange Rate	The following table summarizes the exchange rates used: Nine Months Ended Year Ended March 31, June 30, 2017 2016 2016 2015 Period end Euro : US Dollar exchange rate 1.08 1.14 1.11 1.11 Average period Euro : US Dollar exchange rate 1.09 1.10 1.11 1.20 Period end Mexican Peso : US Dollar exchange rate 0.05 0.06 0.05 0.06 Average period Mexican Peso : US Dollar exchange rate 0.05 0.06 0.06 0.07

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Mar. 31, 2017
Stockholders' Equity Note [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes vested and unvested stock option activity: All Options Vested Options Unvested Options Weighted Weighted Weighted Average Average Average Exercise Exercise Exercise Shares Price Shares Price Shares Price Outstanding at June 30, 2016 2,717,193 1.16 2,517,333 1.17 199,860 1.06 Granted 408,758 1.05 325,000 1.05 83,758 1.05 Options vesting - - 52,224 1.09 (52,224) 1.09 Exercised - - - - - - Forfeited/Cancelled - - - - - - Outstanding at March 31, 2017 3,125,951 $ 1.15 2,894,557 $ 1.15 231,394 $ 1.05
Schedule of Share-based Compensation, by Exercise Price Range	Additional information regarding stock options outstanding and exercisable as of March 31, 2017 is as follows: Option Remaining Exercise Options Contractual Options Price Outstanding Life (in years) Exercisable $ 0.59 8,150 8.91 3,396 0.60 5,000 8.87 2,500 0.65 6,150 7.61 5,125 0.70 225,000 8.68 225,000 0.77 59,500 7.39 55,792 0.80 16,000 8.39 16,000 0.90 25,667 8.35 21,222 0.97 6,000 9.40 - 1.00 370,890 2.53 364,916 1.02 287,000 3.33 287,000 1.05 507,529 9.33 430,630 1.07 53,898 5.55 53,898 1.09 166,165 9.15 43,750 1.10 255,000 8.25 255,000 1.14 3,674 9.89 - 1.15 228,000 5.86 228,000 1.20 31,414 7.14 31,414 1.25 32,000 5.88 32,000 1.30 263,000 4.93 263,000 1.50 380,000 0.81 380,000 1.75 1,067 6.83 1,067 1.80 169,425 6.48 169,425 1.85 24,000 6.14 24,000 1.97 1,422 6.65 1,422 Total 3,125,951 2,894,557
Schedule of Other Share-based Compensation, Activity	The following table summarizes warrant activity: Weighted Average Number of Exercise Warrants Price Outstanding, June 30, 2016 1,990,000 1.25 Granted - - Exercised - - Expired/Cancelled (5,000) 3.75 Outstanding, March 31, 2017 1,985,000 $ 1.25 Exercisable, June 30, 2016 1,990,000 $ 1.25 Exercisable, March 31, 2017 1,985,000 $ 1.25
Schedule of Stockholders' Equity Note, Warrants or Rights	Additional information regarding warrants outstanding and exercisable as of March 31, 2017 is as follows: Remaining Warrant Warrants Contractual Warrants Exercise Price Outstanding Life (in years) Exercisable $ 1.19 100,000 4.73 100,000 1.25 1,885,000 4.20 1,885,000 Total 1,985,000 1,985,000
Schedule of Nonvested Restricted Stock Units Activity	The following table summarizes restricted common stock activity: Weighted Average Number of Grant Date Shares Fair Value Non-vested, June 30, 2016 706,642 0.82 Granted 203,275 1.03 Vested (359,703) 0.81 Forfeited - - Non-vested, March 31, 2017 550,213 $ 0.90

Summary of Significant Accoun15

Summary of Significant Accounting Policies (Details)	3 Months Ended				9 Months Ended
	Mar. 31, 2017		Mar. 31, 2016		Mar. 31, 2017		Mar. 31, 2016
Vendor A [Member]
Concentration Risk, Percentage	16.00%		18.00%		18.00%		16.00%
Vendor B [Member]
Concentration Risk, Percentage		[1]		[1]		[1]	13.00%
[1]	Less than 10%

Summary of Significant Accoun16

Summary of Significant Accounting Policies (Details 1)	9 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Jun. 30, 2016	Jun. 30, 2015
Euro to US Dollar [Member]
Period end exchange rate	1.08	1.14	1.11	1.11
Average period exchange rate	1.09	1.1	1.11	1.2
Mexican Peso to US Dollar [Member]
Period end exchange rate	0.05	0.06	0.05	0.06
Average period exchange rate	0.05	0.06	0.06	0.07

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Jun. 30, 2016
Cash, FDIC Insured Amount	$ 250,000		$ 250,000
Foreign Currency Transaction Loss (Gain), before Tax	6,272	$ (2,829)	$ 27,227	$ 4,293
Customer Concentration Risk [Member]
Concentration Risk, Benchmark Description			Less than 10%
Sales Revenue, Net [Member]
Revenue			10.00%	10.00%
Europe Financial Institutions [Member]
Deposits	$ 181,634		$ 181,634		$ 76,793
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			3,125,951	2,551,028
Employee Stock Option [Member] | Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			1,985,000	205,000

Line of Credit (Details Textual

Line of Credit (Details Textual) - USD ($)	1 Months Ended	9 Months Ended
	Jul. 23, 2010	Mar. 31, 2017	Jun. 30, 2016
Line of Credit Facility, Interest Rate Description		the prime rate plus 5.25%
Line of Credit Facility, Remaining Borrowing Capacity		$ 2,945,000	$ 3,390,000
Line of Credit Facility, Interest Rate at Period End		5.75%
Silicon Valley Bank [Member]
Line of Credit Facility, Amount Outstanding	$ 4,000,000
Line Of Credit Facility Expiration Date 1		Oct. 31, 2017
Debt Instrument, Basis Spread on Variable Rate		2.25%
Line Of Credit Facility Minimum Amount Outstanding During Period		$ 800,000
Debt Instrument, Covenant Description		Financial covenants include maintaining a ratio of quick assets to current liabilities of at least 0.8 to 1.0, and maintaining tangible net worth of $600,000, plus 50% of net income for the fiscal quarter ended from and after December 31, 2015, plus 50% of the dollar value of equity issuances after October 1, 2015 and the principal amount of subordinated debt.
Percentage Of Eligible Accounts Receivable On Line Of Credit	80.00%

Obligations Leases (Details Tex

Obligations Leases (Details Textual)	9 Months Ended
	Mar. 31, 2017USD ($)
Operating Lease Liabilities, Fair Value	$ 463,000
Operating Lease Discount Rate	3.75%
Minimum [Member]
Operating Leases, Rent Expense, Minimum Rentals	$ 10,350
Maximum [Member]
Operating Leases, Rent Expense, Minimum Rentals	$ 11,475

Stockholders' Equity (Details)

Stockholders' Equity (Details)	9 Months Ended
	Mar. 31, 2017$ / sharesshares
Outstanding beginning balance Shares | shares	2,717,193
Granted Shares | shares	408,758
Options vesting Shares | shares	0
Exercised Shares | shares	0
Forfeited/Cancelled Shares | shares	0
Outstanding ending balance Shares | shares	3,125,951
Outstanding beginning balance Weighted Average Exercise Price | $ / shares	$ 1.16
Granted Weighted Average Exercise Price | $ / shares	1.05
Options vesting Weighted Average Exercise Price | $ / shares	0
Exercised Weighted Average Exercise Price | $ / shares	0
Forfeited/Cancelled Weighted Average Exercise Price | $ / shares	0
Outstanding ending balance Weighted Average Exercise Price | $ / shares	$ 1.15
Vested Options [Member]
Outstanding beginning balance Shares | shares	2,517,333
Granted Shares | shares	325,000
Options vesting Shares | shares	52,224
Exercised Shares | shares	0
Forfeited/Cancelled Shares | shares	0
Outstanding ending balance Shares | shares	2,894,557
Outstanding beginning balance Weighted Average Exercise Price | $ / shares	$ 1.17
Granted Weighted Average Exercise Price | $ / shares	1.05
Options vesting Weighted Average Exercise Price | $ / shares	1.09
Exercised Weighted Average Exercise Price | $ / shares	0
Forfeited/Cancelled Weighted Average Exercise Price | $ / shares	0
Outstanding ending balance Weighted Average Exercise Price | $ / shares	$ 1.15
Unvested Options [Member]
Outstanding beginning balance Shares | shares	199,860
Granted Shares | shares	83,758
Options vesting Shares | shares	(52,224)
Exercised Shares | shares	0
Forfeited/Cancelled Shares | shares	0
Outstanding ending balance Shares | shares	231,394
Outstanding beginning balance Weighted Average Exercise Price | $ / shares	$ 1.06
Granted Weighted Average Exercise Price | $ / shares	1.05
Options vesting Weighted Average Exercise Price | $ / shares	1.09
Exercised Weighted Average Exercise Price | $ / shares	0
Forfeited/Cancelled Weighted Average Exercise Price | $ / shares	0
Outstanding ending balance Weighted Average Exercise Price | $ / shares	$ 1.05

Stockholders' Equity (Details 1

Stockholders' Equity (Details 1)	9 Months Ended
	Mar. 31, 2017$ / sharesshares
Options Outstanding	3,125,951
Options Exercisable	2,894,557
Range One [Member]
Option Exercise Price | $ / shares	$ 0.59
Options Outstanding	8,150
Remaining Contractual Life (in years)	8 years 10 months 28 days
Options Exercisable	3,396
Range Two [Member]
Option Exercise Price | $ / shares	$ 0.60
Options Outstanding	5,000
Remaining Contractual Life (in years)	8 years 10 months 13 days
Options Exercisable	2,500
Range Three [Member]
Option Exercise Price | $ / shares	$ 0.65
Options Outstanding	6,150
Remaining Contractual Life (in years)	7 years 7 months 10 days
Options Exercisable	5,125
Range Four [Member]
Option Exercise Price | $ / shares	$ 0.70
Options Outstanding	225,000
Remaining Contractual Life (in years)	8 years 8 months 5 days
Options Exercisable	225,000
Range Five [Member]
Option Exercise Price | $ / shares	$ 0.77
Options Outstanding	59,500
Remaining Contractual Life (in years)	7 years 4 months 20 days
Options Exercisable	55,792
Range Six [Member]
Option Exercise Price | $ / shares	$ 0.80
Options Outstanding	16,000
Remaining Contractual Life (in years)	8 years 4 months 20 days
Options Exercisable	16,000
Range Seven [Member]
Option Exercise Price | $ / shares	$ 0.90
Options Outstanding	25,667
Remaining Contractual Life (in years)	8 years 4 months 6 days
Options Exercisable	21,222
Range Eight [Member]
Option Exercise Price | $ / shares	$ 0.97
Options Outstanding	6,000
Remaining Contractual Life (in years)	9 years 4 months 24 days
Options Exercisable	0
Range Nine [Member]
Option Exercise Price | $ / shares	$ 1
Options Outstanding	370,890
Remaining Contractual Life (in years)	2 years 6 months 11 days
Options Exercisable	364,916
Range Ten [Member]
Option Exercise Price | $ / shares	$ 1.02
Options Outstanding	287,000
Remaining Contractual Life (in years)	3 years 3 months 29 days
Options Exercisable	287,000
Range Eleven [Member]
Option Exercise Price | $ / shares	$ 1.05
Options Outstanding	507,529
Remaining Contractual Life (in years)	9 years 3 months 29 days
Options Exercisable	430,630
Range Twelve [Member]
Option Exercise Price | $ / shares	$ 1.07
Options Outstanding	53,898
Remaining Contractual Life (in years)	5 years 6 months 18 days
Options Exercisable	53,898
Range Thirteen [Member]
Option Exercise Price | $ / shares	$ 1.09
Options Outstanding	166,165
Remaining Contractual Life (in years)	9 years 1 month 24 days
Options Exercisable	43,750
Range Fourteen [Member]
Option Exercise Price | $ / shares	$ 1.10
Options Outstanding	255,000
Remaining Contractual Life (in years)	8 years 3 months
Options Exercisable	255,000
Range Fifteen [Member]
Option Exercise Price | $ / shares	$ 1.14
Options Outstanding	3,674
Remaining Contractual Life (in years)	9 years 10 months 20 days
Options Exercisable	0
Range Sixteen [Member]
Option Exercise Price | $ / shares	$ 1.15
Options Outstanding	228,000
Remaining Contractual Life (in years)	5 years 10 months 10 days
Options Exercisable	228,000
Range Seventeen [Member]
Option Exercise Price | $ / shares	$ 1.20
Options Outstanding	31,414
Remaining Contractual Life (in years)	7 years 1 month 20 days
Options Exercisable	31,414
Range Eighteen [Member]
Option Exercise Price | $ / shares	$ 1.25
Options Outstanding	32,000
Remaining Contractual Life (in years)	5 years 10 months 17 days
Options Exercisable	32,000
Range Nineteen [Member]
Option Exercise Price | $ / shares	$ 1.30
Options Outstanding	263,000
Remaining Contractual Life (in years)	4 years 11 months 5 days
Options Exercisable	263,000
Range Twenty [Member]
Option Exercise Price | $ / shares	$ 1.50
Options Outstanding	380,000
Remaining Contractual Life (in years)	9 months 22 days
Options Exercisable	380,000
Range Twenty One [Member]
Option Exercise Price | $ / shares	$ 1.75
Options Outstanding	1,067
Remaining Contractual Life (in years)	6 years 9 months 29 days
Options Exercisable	1,067
Range Twenty Two [Member]
Option Exercise Price | $ / shares	$ 1.80
Options Outstanding	169,425
Remaining Contractual Life (in years)	6 years 5 months 23 days
Options Exercisable	169,425
Range Twenty Three [Member]
Option Exercise Price | $ / shares	$ 1.85
Options Outstanding	24,000
Remaining Contractual Life (in years)	6 years 1 month 20 days
Options Exercisable	24,000
Range Twenty Four [Member]
Option Exercise Price | $ / shares	$ 1.97
Options Outstanding	1,422
Remaining Contractual Life (in years)	6 years 7 months 24 days
Options Exercisable	1,422

Stockholders' Equity (Details 2

Stockholders' Equity (Details 2) - Warrant [Member] - $ / shares	9 Months Ended
	Mar. 31, 2017	Jun. 30, 2016
Non-vested, Beginning balance	1,990,000
Number of Warrants, Granted	0
Number of Warrants, Exercised	0
Number of Warrants, Expired/Cancelled	(5,000)
Non-vested, Ending balance	1,985,000
Number of Warrants, Exercisable	1,985,000	1,990,000
Weighted Average Exercise Price, Outstanding Beginning balance	$ 1.25
Weighted Average Exercise Price, Granted	0
Weighted Average Exercise Price, Exercised	0
Weighted Average Exercise Price, Expired/Cancelled	3.75
Weighted Average Exercise Price, Outstanding Ending balance	1.25
Weighted Average Exercise Price, Exercisable	$ 1.25	$ 1.25

Stockholders' Equity (Details 3

Stockholders' Equity (Details 3) - Warrant [Member] - $ / shares	3 Months Ended
	Mar. 31, 2017	Jun. 30, 2016
Warrant Exercise Price	$ 1.25	$ 1.25
Warrants Outstanding	1,985,000	1,990,000
Warrants Exercisable	1,985,000	1,990,000
Range One [Member]
Warrant Exercise Price	$ 1.19
Warrants Outstanding	100,000
Warrants Outstanding Remaining Contractual Life (in years)	4 years 8 months 23 days
Warrants Exercisable	100,000
Range Two [Member]
Warrant Exercise Price	$ 1.25
Warrants Outstanding	1,885,000
Warrants Outstanding Remaining Contractual Life (in years)	4 years 2 months 12 days
Warrants Exercisable	1,885,000

Stockholders' Equity (Details 4

Stockholders' Equity (Details 4) - Restricted Common Stock	9 Months Ended
	Mar. 31, 2017$ / sharesshares
Non-vested, Beginning balance | shares	706,642
Number of shares, Granted | shares	203,275
Number of shares, Vested | shares	(359,703)
Number of shares, Forfeited | shares	0
Non-vested, Ending balance | shares	550,213
Weighted Average Grant Date Fair Value, Outstanding Beginning Balance | $ / shares	$ 0.82
Weighted Average Grant Date Fair Value, Granted | $ / shares	1.03
Weighted Average Grant Date Fair Value, Vested | $ / shares	0.81
Weighted Average Grant Date Fair Value, Forfeited | $ / shares	0
Weighted Average Grant Date Fair Value, Outstanding Ending Balance | $ / shares	$ 0.9

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	9 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Jun. 30, 2016	Nov. 10, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	2,231,753
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	5 years 9 months 22 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	5 years 6 months 14 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	$ 185,399
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	178,278
Stock or Unit Option Plan Expense	0	$ 29,815
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	113,069
Stock Issued During Period, Value, Restricted Stock Award, Gross	270,787
Stock Repurchased During Period, Value	$ 90,328
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	408,758
Proceeds from Stock Options Exercised	$ 247,224	$ 245,523
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	77.80%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	81.40%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	1.27%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	2.06%
Employees and Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	408,758
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 248,549
Restricted Stock [Member]
Stock or Unit Option Plan Expense			$ 783,845
Stock Issued During Period, Shares, Restricted Stock Award, Gross			1,303,687
Stock Issued During Period, Value, Restricted Stock Award, Gross			$ 1,286,474
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options	$ 442,567
Restricted Stock [Member] | Employees [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	203,275
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 210,365
Repurchase Program [Member]
Stock Repurchased During Period, Shares	86,958
Treasury Stock Acquired, Average Cost Per Share	$ 1.04
Stock Repurchased During Period, Value	$ 90,329
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant				5,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years
Minimum [Member] | Restricted Stock [Member] | Employees [Member]
Sale of Stock, Price Per Share	$ 0.97
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant				7,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	6 years
Maximum [Member] | Restricted Stock [Member] | Employees [Member]
Sale of Stock, Price Per Share	$ 1.14